ABSTRACT Objectives
Rheumatoid arthritis (RA) is a chronic, systemic infl ammatory disease that results in joint destruction and disability. 1 Levels of tumour necrosis factor alpha (TNF), an infl ammatory cytokine, are elevated in the blood and synovial fl uid of patients with RA, and may play a central role in its pathogenesis. 2 -7 Although infl iximab, an anti-TNF antibody, exhibits excellent effectiveness in RA, 8 -11 insufficient response to the standard treatment of infl iximab (3 mg/kg per 8 weeks) has also been observed in some cases in clinical practice. Such patients are usually treated by dose escalation or by shortening the dose interval of the infl iximab therapy. 12 -15 The RISING study (NCT00691028) is a randomised, double-blind clinical trial, which has shown that the clinical response to infl iximab at a dose of 10 mg/kg is signifi cantly higher than the response to 3 mg/kg infl iximab, and that a trough serum level of 1 μg/ml is the threshold for clinical response. 16 However, clinical response to different dose levels of infl iximab was signifi cant only for American College of Rheumatology (ACR) improvement criteria and the European League Against Rheumatism (EULAR) responses, and the measurable difference was small.
Several clinical studies have attempted to address whether a higher dose of infl iximab provides a better clinical response than standard doses in patients with RA. 8 -11 17 However, the results were not consistent among those studies. In addition, a randomised, double-blind study comparing dose escalation and continuation of the standard dose in patients with RA who had an insuffi cient response to 3 mg/kg of infl iximab clearly demonstrated no benefi cial response by dose escalation, 18 contrary to our results.
Although the standard dose of infl iximab can be effi cacious in a large proportion of patients with RA, some patients may require a higher dose of infl iximab to achieve clinical response. 19 20 The inconsistent results mentioned above might be explained by the different proportion of patients who might benefi t from infl iximab dose escalation in each study. Thus the clinical and immunological features of these patients who require higher dose of infl iximab are not fully understood.
It is tempting to speculate that the production and resultant plasma levels of TNF, the target molecule of infl iximab, exceeds the neutralising capacity of infl iximab in insuffi cient responders who are unable to maintain the threshold serum level of infliximab. Considering that hypothesis, we analysed the RISING study data based on plasma TNF levels. We found that the clinical response of patients with high baseline levels of TNF (baseline-TNF) showed a signifi cant improvement with higher doses of infliximab, whereas patients with low baseline-TNF did not have a better response even with higher doses of infl iximab.
METHODS

Patients and study protocol
The study protocol was approved by the local institutional review board and was carried out in accordance with the Helsinki Declaration and good clinical practice. Patient enrollment criteria and study design have previously been described in detail. 16 In the RISING study, 327 patients with active RA, despite receiving previous treatment with methotrexate, were administered 3 mg/kg infl iximab at weeks 0, 2 and 6 with methotrexate less than 0.55 pg/ml, and a threefold higher level, 1.65 pg/ml, were adopted as cut-off values, and the patients were stratifi ed into the following three patient groups for analysis: low, less than 0.55 pg/ml (TNF-low); intermediate, 0.55 pg/ml or greater to less than 1.65 pg/ml (TNF-int); and high, 1.65 pg/ml or greater (TNF-high).
The association of baseline-TNF with baseline disease activity and the effi cacy of infl iximab therapy was analysed for the three groups described above (TNF-low, TNF-int and TNFhigh patients) employing the Kendall rank correlation coeffi cient. Baseline disease activity was analysed for the enrolled patients (n=327). Clinical responses (DAS28-CRP or ACR core set) and effi cacy on physical function (improved health assessment questionnaire (HAQ) score) at week 54 were analysed using the last observation carried forward approach (n=307). Radiographic progression was analysed in the patients whose radiographic data were obtained at week 54 (n=273). The association between the serum infl iximab level and clinical response or disease activity at week 54 was analysed in the patients for whom both serum levels and DAS28-CRP values were obtained at week 54 (n=271).
Primary non-responders were defi ned as patients who had not achieved LDA throughout the study period (at weeks 2-54), and secondary non-responders as those who had not achieved LDA at week 54 but had achieved it at least once between weeks 2 and 50. Kruskal-Wallis test analysis was performed to compare the rates of TNF-low, TNF-int and TNF-high patients in primary and secondary non-responders versus responders (those who had achieved LDA at week 54).
RESULTS
Patients' background and association between baseline-TNF and parameters of disease activity at baseline Table 1 shows the baseline demographics and clinical characteristics of the enrolled patients (n=327). The median (IQR), minimum and maximum baseline-TNF values were 0.92 pg/ml (<0.55-1.29 pg/ml), less than 0.55 pg/ml and 9.68 pg/ml, respectively. The proportion of patients with baseline-TNF values less than 0.55 pg/ml (undetectable), 0.55 pg/ml or greater to less than 1.65 pg/ml, and 1.65 pg/ml or greater (TNF-low, TNF-int and TNF-high patients) was 28.7%, 58.4% and 12.8%, respectively. Details on the distribution of baseline-TNF can be found in supplementary fi gure 1 (available online only). Baseline-TNF was signifi cantly, but slightly, correlated with most parameters of disease activity and HAQ score, but not with radiographic progression ( table 2 ). The signifi cant correlations of baseline-TNF with RF and anti-CCP antibodies were also observed.
Clinical response to infl iximab at week 54
Of the enrolled patients, 307 were treated with 3, 6 or 10 mg/kg infl iximab during the blinded period, and clinical response was evaluated at week 54 using DAS28-CRP ( fi gure 1 ). The clinical responses at week 54 were signifi cantly higher in the 10 mg/kg group than in the 3 mg/kg group, and 45.2% of the patients in the 10 mg/kg group achieved DAS28-CRP remission.
Association between baseline-TNF and the effi cacy of infl iximab therapy at week 54
The EULAR responses and disease activities at week 54 in TNFlow (n=87), TNF-int (n=180), and TNF-high (n=40) patients are shown in fi gure 2A,B . In TNF-low patients, the clinical response was similar among the 3, 6 and 10 mg/kg groups, showing no dose dependency. In TNF-int patients, the EULAR (open-label period weeks 0-14). Patients were randomly assigned into three groups using a dynamic allocation procedure based on the clinical response at week 10 and were treated with 3 (n=99), 6 (n=104), or 10 (n=104) mg/kg infl iximab, every 8 weeks from weeks 14 to 46, with methotrexate (blinded period weeks 14-54).
Laboratory test values and serum infl iximab measurement
Plasma samples for the evaluation of baseline-TNF were collected just before the fi rst infusion of infl iximab (week 0). The plasma was separated from EDTA-supplemented blood and was stored at −20 to −80°C. Baseline-TNF levels were measured by ELISA using the QantiGlo ELISA Kit (QTA00B; R&D Systems Inc, Minneapolis, Minnesota, USA) in Mitsubishi Chemical Medience Corporation (Tokyo, Japan). Recombinant human TNF included in the kit was used as reference. Mitsubishi Chemical Medience Corporation has made minor modifi cations on the assay procedure of the ELISA kit ( http://www.rndsystems.com/ pdf/qta00b.pdf ) and has validated their detection limit. Since the mean relative light units (2 SD) at blank and 0.55 pg/ml were 15.2 (3.4) and 25.2 (5.0) by their modifi ed procedure, respectively, the detection limit was determined as 0.55 pg/ml by adding 2 SD to the relative light units. The coeffi cient of variation or relative error values of intra-assay or inter-assay TNF were within 3.6% or 6.2%, respectively. They confi rmed that freezing and thawing the plasma sample 10 times and storing at −20°C for 22 weeks did not affect the stability of TNF in the plasma.
Sera were collected at weeks 0 and 2 and every 4 weeks thereafter. The serum infl iximab level was measured by ELISA using the anti-infl iximab monoclonal antibody obtained from Centocor Ortho Biotech Inc. (Horsham, Pennsylvania, USA). 8 Serum infl iximab levels below 0.1 μg/ml were undetectable.
Baseline rheumatoid factor (RF) was measured by the latex agglutination test. Antibodies against cyclic citrullinated peptides (CCP) and matrix metalloproteinase-3 (MMP-3) levels were measured by ELISA. The detectable ranges were as follows: RF, 3 IU/ml or greater; anti-CCP antibodies, 0.6 IU/ml or greater to 100 IU/ml or less; and MMP-3, 12.5 ng/ml or greater.
Evaluation of effi cacy
The clinical response to infl iximab was evaluated using EULAR criteria, and disease activity was assessed using the disease activity score in 28 joints (DAS28) based on C-reactive protein (CRP) and the ACR core set 21 at week 54. The EULAR response was evaluated using the DAS28 based on the erythrocyte sedimentation rate (ESR) assessment method ( http://www. reuma-nijmegen.nl/www.das-score.nl/index.html ). The cut-off values for DAS28-CRP were as follows, based on a report from Inoue et al . 22 : DAS28-CRP remission, less than 2.3; low disease activity (LDA), 2.3 or greater to less than 2.7; moderate disease activity (MDA), 2.7 or greater to 4.1 or less; high disease activity (HDA), greater than 4.1. Joint damage was assessed by the total modifi ed Sharp score (0-390 points). 23 
Analytical method
The clinical responses to infl iximab at week 54 were analysed for the full analysis set using the last observation carried forward approach. For the comparison of clinical response among dose groups (3, 6 and 10 mg/kg), logistic regression analysis was performed using the clinical responses at the time of randomisation (week 10) as a covariate.
Because there is no well-established threshold value for an abnormal TNF level in the ELISA kit used, the detection limit, On the other hand, those of primary non-responders (n=88) were 21.6%, 62.5% and 15.9%, and those of secondary nonresponders (n=71) were 23.9%, 57.7% and 18.3%, respectively. Signifi cant differences were observed between the responders and both of the non-responders (p=0.016 and p=0.032, respectively).
Association between baseline-TNF and serum infl iximab level
Clinical response to infl iximab has been shown to be infl uenced by trough serum infl iximab levels, and the threshold level for clinical response is approximately 1 μg/ml. 20 24 In this study, the median (IQR) serum infl iximab level at week 54 in patients with EULAR good response, moderate response and no response was 3.1 (1.2-7.1), 1.2 (<0.1-3.6) and less than 0.1 (<0.1-0.4) μg/ml. The median (IQR) level in patients in DAS28-CRP remission, with LDA, with MDA and with HDA at week 54 was 3.4 (1.5-7.5), 2.1 (0.4-4.7), 1.4 (<0.1-4.0) and less than 0.1 (<0.1-0.7) μg/ml, respectively. A signifi cant association was observed between clinical response or disease activity and the serum infl iximab level (both p<0.001). In patients with high trough serum infl iximab levels, better clinical responses were attained. Meanwhile, in patients with poor clinical response (EULAR no response, high disease activity), the median trough serum level was undetectable (<0.1 μg/ml).
Baseline-TNF greatly affected the serum infl iximab levels ( fi gure 3A-C ). In TNF-low patients, the median trough serum infliximab levels were equivalent to or greater than the threshold level (1 μg/ml) in all groups (3, 6 and 10 mg/kg). For TNF-int patients, the 3 mg/kg dose did not achieve the threshold level of infl iximab but did provide a detectable level (≥0.1 μg/ml). However, in TNF-high patients, the median trough serum infl iximab levels were undetectable at both 3 and 6 mg/kg doses, in contrast to the 10 mg/kg dose, at which a high level (>2 μg/ml) was maintained.
The positive rates for anti-infl iximab antibodies (human antichimeric antibodies; HACA), which is reported to infl uence the serum infl iximab level 25 were 27.3%, 23.1% and 12.5% in the 3, 6 and 10 mg/kg dose levels, respectively. In patients who were negative for HACA, the serum infl iximab level was also lower in TNF-high patients than in TNF-low patients, and the median serum infl iximab levels at the 3 mg/kg dose at week 54 in TNFlow patients (n=23), TNF-int patients (n=37) and TNF-high patients (n=8) were 1.0, 0.6 and 0.2 μg/ml, respectively.
Association between safety and baseline-TNF or serum infl iximab level
The incidences of adverse events (total, serious events, infection, serious infection, or infusion reaction) were almost comparable among patients receiving 3, 6 and 10 mg/kg doses in TNF-low, TNF-int and TNF-high patients. We could fi nd no clear association between the incidence of adverse events and the trough serum level of infl iximab either (supplementary table 3, available online only).
DISCUSSION
Although dose escalation or shortening of the administration interval between administrations has been used for patients with RA who show an insuffi cient response to the standard dose of infl iximab (3 mg/kg for 8 weeks after initial induction), the effectiveness of these countermeasures is still controversial. 18 -20 26 -32 In this report, we hypothesised that the production and resultant plasma level of TNF exceeds the neutralising capacity of infl iximab in insuffi cient responders; and that infl iximab is consumed response rate increased and disease activity decreased as the dose increased, but without signifi cant difference. For TNFhigh patients, the clinical response and disease activity were signifi cantly better at 10 mg/kg than at 3 mg/kg and 6 mg/kg. The good response rates were 14%, 31% and 60% in the 3, 6 and 10 mg/kg groups, respectively, and the DAS28-CRP remission rates were 7%, 31% and 50%, respectively. A similar infl uence by baseline-TNF was also noted on the ACR core set ( fi gure 2C ). Signifi cant dose dependency was observed only in TNF-high patients. Baseline-TNF at clinical response is shown in supplementary table 1 (available online only). Clinical response was signifi cantly infl uenced by baseline-TNF in the 3 mg/kg group, but not in the 6 and 10 mg/kg groups. Baseline-TNF also infl uenced the improving physical function, in which the improvement in the HAQ score values and the rates of patients with meaningful improvement (>0.22) in all dosage groups were signifi cantly different in TNF-high patients (supplementary table 2, available online only). Meanwhile, none of the groups showed signifi cant association with radiographic progression.
The proportions of TNF-low, TNF-int and TNF-high patients in responders (n=148) were 34.5%, 56.8% and 8.8%, respectively. this association was not refl ected by the presence of HACA status.
It has been suggested that the threshold serum level for infl iximab effi cacy on radiographic progression might be lower than that for clinical response. 33 In this study, approximately 90% of the patients whose serum level could be maintained over the threshold for radiographic progression, including even TNF-high patients, showed no radiographic progression. It may explain why baseline-TNF status had no infl uence on radiographic progression as observed in this study.
The present report has demonstrated that higher doses of infl iximab exhibited signifi cantly better clinical and functional response in patients with high baseline-TNF, whereas clinical and functional response was comparable among patients administered 3, 6 and 10 mg/kg of infl iximab with low baseline-TNF.
We had reported previously that there was no difference in the safety profi le among groups receiving 3, 6 or 10 mg/kg. 16 The rates of adverse events were almost comparable among all dosage groups in TNF-low, TNF-int and TNF-high patients. However, it has been reported that high-dose infl iximab therapy might increase the risk of adverse events. 11 34 35 So, the balance between risk and benefi t should be considered at the time of infl iximab dose escalation, even in TNF-high patients.
There have been several reports on the association between TNF level and the effi cacy of infl iximab. 36 -39 Although the reason for the inconsistent results is unclear, the serum TNF level was measured by bioassay in the report by Marotte et al , 37 which is different from this study, in which ELISA was employed. In the studies by Wijbrandts et al , 38 clinical response was evaluated at week 16, 2 weeks after infl iximab administration when a high serum infl iximab level may have been maintained even in patients with a high baseline-TNF. These differences may have led to the different conclusions.
In the RISING study, baseline-TNF was measured in one institution (Mitsubishi Chemical Medience Corporation) concurrently, where minor modifi cations were made in the original assay procedure and validated for the commercial use of clinical samples.
to neutralise the TNF, decreasing the serum infl iximab level in those patients.
In our study, clinical responses at doses of 3, 6 and 10 mg/kg of infl iximab were comparable in TNF-low patients, and the minimum serum infl iximab level required for clinical response (approximately 1 μg/ml) was maintained, even in the 3 mg/ kg group. Accordingly, the maximal clinical responses can be achieved even with 3 mg/kg therapy in TNF-low patients. In other words, dose escalation does not provide any benefi t in this population. In contrast, in TNF-high patients, clinical responses at 3 and 6 mg/kg were signifi cantly decreased in comparison with the response to a 10 mg/kg dose. The trough serum infl iximab levels were 'undetectable' at 3 and 6 mg/ kg but were greater than 2 μg/ml with a 10 mg/kg dose. As the association between baseline-TNF and the serum infl iximab level was also observed in HACA-negative patients, Table 2 Baseline disease activities in TNF-low, TNF-int and TNF-high patients Baseline disease activities were evaluated in the patients enrolled in the RISING study (n=327). The associations of baseline-tumour necrosis factor alpha (TNF) with baseline disease activities were analysed in the three groups (TNF-low, TNF-int and TNF-high patients) employing the Kendall rank correlation coeffi cient. *n=93. † n=190. CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MMP-3, matrix metalloproteinase 3; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TSS, total modifi ed Sharp score; VAS, visual analogue scale. Response rate at week 54 (%) Figure 1 Clinical responses to infl iximab therapy in patients with rheumatoid arthritis at week 54. The European League Against Rheumatism response criteria and disease activity were measured by the disease activity score in 28 joints (DAS28)-C-reactive protein (CRP) using the last observation carried forward method. Disease activity was defi ned as high disease activity, DAS28-CRP greater than 4.1; moderate disease activity, 2.7 or greater to 4.1 or less; low disease activity, 2.3 or greater to less than 2.7; and DAS28-CRP remission, less than 2.3. *p<0.05 versus the 3 mg/kg groups.
Figure 2
Correlation of plasma tumour necrosis factor alpha (TNF) levels before infl iximab therapy (baseline-TNF) with (A) the European League Against Rheumatism (EULAR) response, (B) the disease activity score in 28 joints (DAS28) and (C) American College of Rheumatology (ACR) core set at week 54. Patients were divided into three patients groups by the baseline-TNF level as follows: TNF-low patients, less than 0.55 pg/ml; TNF-int patients, 0.55 pg/ml or greater to less than 1.65 pg/ml; and TNF-high patients, 1.65 pg/ml or greater. EULAR response criteria for disease activity were measured by DAS28-C-reactive protein (CRP). Disease activity was defi ned as high disease activity (HDA), DAS28-CRP greater than 4. CRP was reported to be associated with the serum infl iximab level, 47 but no consensus has been obtained about the correlation between baseline CRP and clinical response. 36 48 We investigated the infl uence of baseline CRP on the clinical response as an index of EULAR response as done by baseline-TNF. However, we could fi nd no clear relationship between them (supplementary fi gure 3A,B, available online only). Given that TNF is one of the key cytokines that induce CRP in various infl ammatory diseases such as RA, it is reasonable that baseline-TNF, rather than CRP, would be a good predictor of clinical response to the TNF inhibitor, infl iximab. Many contradictory reports have been published regarding the effectiveness of dose escalation with infl iximab. 18 -20 26 -32 The reason why no consensus has been reached is that dose escalation is signifi cant only in TNF-high patients, so the results of reports have been infl uenced by the number of patients with high baseline-TNF included in those studies. In the RISING study, TNF-high patients accounted for approximately 13% of the total.
This study may provide insight into our understanding of the relationship between the concentration of circulating cytokines and the dose of antibodies against the cytokines in the treatment of RA. As mentioned by van Vollenhoven, 26 an attempt to apply results obtained under highly controlled circumstances at the group level to the unique individual is necessary. These results may be useful for establishing treatment strategies, such as the appropriate dose of infl iximab in accordance with baseline-TNF in patients with RA, not only in daily clinical practice but also in relation to the economics of health care.
It was reported that RF in the samples may cause false-positive results in immunoassays by cross-linking the capture and detection antibodies. 40 In our study, a signifi cant correlation was observed between TNF and RF at baseline (τ value 0.129, p<0.001). However, the maximum baseline RF level was 1560 IU/ml in patients with undetectable baseline-TNF (supplementary fi gure 2, available online only). Therefore, we considered that RF might interfere with the assay of TNF in patients with greater than 1560 IU/ml, but not in patients with less than 1560 IU/ml. Furthermore, we freshly collected the plasma samples from 39 patients with RA (in which backgrounds were shown in supplementary table 4, available online only), and carried out several tests to evaluate the effects of RF on the ELISA for TNF: 'RF-blocking test', using 40% mouse serum, 20% goat serum and 20% rabbit serum; 41 42 'IgM-RF adding test', using purifi ed polyclonal IgM-RF (Interference Check RF Plus; Sysmex Corporation, Kobe, Japan); 'mismatch simplex sandwich test', 42 using anti-interleukin 6 antibodies conjugated to horseradish peroxidase from the QantiGlo ELISA Kit for interleukin 6 (Q6000B; R&D Systems Inc) as the detection antibodies. As we did not fi nd a clear signal indicating that RF interacted with our ELISA for TNF, we considered that the TNF levels in our study were not infl uenced by RF (supplementary tables 5-7, available online only).
The circulating TNF level in patients with RA varied from several pg/ml to greater than 100 pg/ml in different reports. 43 -46 Although the patient background should be considered in determining the cause of the variation, the measurement systems used for detecting circulating TNF levels in individual studies may largely account for the variation. In that regard, the cut-off values for baseline-TNF used in this report (0.55 and 1.65 pg/ml) were not absolute, and the titre should be standardised in the future.
So far, some of the patient backgrounds have been investigated for predictors of their clinical response to infl iximab. Baseline Figure 3 Serum infl iximab levels in (A) tumour necrosis factor alpha (TNF)-low, (B) TNF-int and (C) TNF-high patients. Patients were divided into three groups by the plasma TNF level before infl iximab therapy (baseline-TNF) as follows: TNF-low patients, less than 0.55 pg/ml; TNF-int patients, 0.55 pg/ml or greater to less than 1.65 pg/ml; and TNF-high patients, 1.65 pg/ml or greater. Serum infl iximab levels were measured by ELISA. TNF-high patients C
